Related Experiment Video
Updated: Jun 13, 2026
11:31
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Dendritic cell-based therapy in Type 1 diabetes mellitus
Brett Phillips1, Nick Giannoukakis, Massimo Trucco
1University of Pittsburgh School of Medicine, Department of Pediatrics, Division of Immunogenetics, Children's Hospital of Pittsburgh, Rangos Research Center, 530 45th Street, Pittsburgh, PA 15201, USA. bep14@pitt.edu
Expert Review of Clinical Immunology
|May 19, 2010
Summary
Dendritic cell (DC) immunotherapy shows promise for treating autoimmune diseases like type 1 diabetes. These engineered cells aim to induce immune tolerance, potentially preventing organ transplant rejection and autoimmune conditions.
Area of Science:
- Immunology
- Cell Therapy
- Transplantation
Background:
- Dendritic cells (DCs) play a crucial role in immune regulation and have shown potential in managing autoimmune disorders and transplant rejection.
- Despite extensive research for two decades, DC-based therapies are now advancing into human clinical trials.
- Type 1 diabetes is the first autoimmune disease targeted for human treatment using autologous-engineered DCs.
Purpose of the Study:
- To review the role of dendritic cells (DCs) in the development of autoimmunity.
- To discuss the engineering strategies for DCs to treat autoimmune disorders.
- To highlight the potential of DC immunotherapy in clinical applications.
Main Methods:
- Review of existing literature on DC immunotherapy in autoimmunity and transplantation.
- Analysis of preclinical studies using engineered DCs in rodent models of autoimmune disease.
- Examination of mechanisms for inducing immune hyporesponsiveness and modulating immune cell networks.
Main Results:
- Dendritic cell immunotherapy is a feasible approach for prolonging transplant survival and preventing autoimmunity.
- Engineered DCs can induce antigen-specific or cell-specific immune hyporesponsiveness.
- DCs can indirectly modulate immune responses through other immune cell networks.
Conclusions:
- Dendritic cell immunotherapy is transitioning from research to clinical reality, with type 1 diabetes as a primary target.
- Engineered DCs offer a promising therapeutic strategy for autoimmune disorders by modulating immune responses.
- Further clinical trials are warranted to establish the efficacy and safety of DC-based therapies.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...